Skip to main content
SpringerLink
Log in

Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature

  • Case Report
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

A 90-year-old man presented with subcutaneous ecchymoses. He had been under treatment with dabigatran etexilate methanesulfonate (DEM). Prolonged APTT and decreased PT was developed 2 months after the start of DEM, more prolonged 6 months later. DEM was discontinued, the coagulopathy did not improve. Factor V activity was decreased, along with appearance of coagulation factor V inhibitor (FVI). He did not have antiphospholipid syndrome or malignancy. He was diagnosed as having acquired FVI caused by DEM. Steroid pulse therapy was effective. There have been 74 reported cases of AFVI induced by drug treatment, but none after treatment with DEM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ortel TL (1999) Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 133:326–334

    Article  PubMed  CAS  Google Scholar 

  2. Gartrell B (2011) Acquired factor V inhibitor complicating warfarin therapy. Am J Hematol 86:710–712

    Article  PubMed  Google Scholar 

  3. Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859

    PubMed  CAS  Google Scholar 

  4. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162

    PubMed  CAS  Google Scholar 

  5. Horder MH (1955) Isolated factor V deficiency caused by a specific inhibitor (in German). Acta Haematol 13:235–241

    Article  PubMed  CAS  Google Scholar 

  6. Favaloro EJ, Posen J, Ramakrishna R, Soltani S, McRae S, Just S et al (2004) Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 15:637–647

    Article  PubMed  Google Scholar 

  7. Franchini M, Lippi G (2011) Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31:449–457

    Article  PubMed  CAS  Google Scholar 

  8. Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26

    Article  PubMed  Google Scholar 

  9. Shanmugam H, Jayaranee S, Eow GI (2011) A case report of an acquired inhibitor to coagulation factor V. Haemophilia 17:168–170

    Article  PubMed  CAS  Google Scholar 

  10. Nozu T, Mita H, Okumura T (2010) Acquired factor V inhibitor in a patient with a mechanical aortic valve under warfarin therapy. Intern Med 49:2229–2233

    Article  PubMed  Google Scholar 

  11. Endo H, Kawauchi K, Tomimatsu M, Iga D, Ogasawara T, Yasuyama M et al (2007) Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers. Intern Med 46:621–625

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Juntendo University Urayasu Hospital, 1-1, 2-Chome, Tomioka, Urayasu, Chiba, Japan

    Yasunobu Sekiguchi, Hitomi Yoshikawa, Asami Shimada, Hidenori Imai, Mutsumi Wakabayashi, Keiji Sugimoto, Norio Komatsu & Masaaki Noguchi

  2. Department of Laboratory Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan

    Noriko Nakamura & Tomohiro Sawada

  3. Department of Cardiology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan

    Tetsuo Ichinose

  4. Department of Cardiology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan

    Dai Ozaki

Authors
  1. Yasunobu Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitomi Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asami Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidenori Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mutsumi Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keiji Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noriko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomohiro Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuo Ichinose
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dai Ozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Norio Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masaaki Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasunobu Sekiguchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sekiguchi, Y., Yoshikawa, H., Shimada, A. et al. Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature. Indian J Hematol Blood Transfus 30 (Suppl 1), 275–279 (2014). https://doi.org/10.1007/s12288-014-0358-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-014-0358-4

Keywords

Search

Navigation